Literature DB >> 20970870

Comparison of fasting capillary glucose variability between insulin glargine and NPH.

Panwei Mu1, Hongyun Lu, Guochao Zhang, Yanming Chen, Jingyi Fu, Manman Wang, Jiong Shu, Longyi Zeng.   

Abstract

The aim of this study was to compare coefficient of variation of fasting capillary blood glucose (FBG) between insulin glargine and NPH in T2DM with poorly controlled by oral antidiabetic drugs. The results demonstrated that insulin glargine was more potent in improving glycemic control than NPH with stable FBG. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20970870     DOI： 10.1016/j.diabres.2010.09.026

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  5 in total

1.  International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.

Authors:  Geremia B Bolli; Larry C Deeb; Satish K Garg; John L Leahy; Roger S Mazze; David R Owens; Matthew C Riddle; Phil Southerland; Ellie S Strock
Journal:  Diabetes Technol Ther       Date:  2011-09       Impact factor: 6.118

2.  (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

Authors:  Thomas Semlitsch; Jennifer Engler; Andrea Siebenhofer; Klaus Jeitler; Andrea Berghold; Karl Horvath
Journal:  Cochrane Database Syst Rev       Date:  2020-11-09

Review 3.  Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis.

Authors:  Shuang Liang; Hang Yin; Chunxiang Wei; Linjun Xie; Hua He; Xiaoquan Liu
Journal:  J Diabetes Metab Disord       Date:  2017-11-14

4.  Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia.

Authors:  Asrul Akmal Shafie; Chin Hui Ng
Journal:  Clinicoecon Outcomes Res       Date:  2020-06-22

Review 5.  Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus.

Authors:  Bipin Sethi; A G Unnikrishnan; Vageesh Ayyar; P K Jabbar; K K Ganguly; Sudhir Bhandari; Ashu Rastogi; Rajarshi Mukherjee; Vivek Sundaram; Adlyne R Asirvatham
Journal:  Diabetes Ther       Date:  2022-06-30       Impact factor: 3.595
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.